Metabolic and Immune Activation Effects of Treatment Interruption in Chronic HIV-1 Infection: Implications for Cardiovascular Risk

Autor: Roy M. Matining, David Katzenstein, William Keith Henry, Laurie Myers, Hernan Valdez, Pablo Tebas, John L. Schmitz, Deborah Weng-Cherng, William G. Powderly, Nasreen C. Jahed
Jazyk: angličtina
Rok vydání: 2008
Předmět:
Interleukin 2
medicine.medical_specialty
lcsh:Medicine
Viremia
Inflammation
HIV Infections
Disease
030204 cardiovascular system & hematology
law.invention
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Randomized controlled trial
law
Risk Factors
Internal medicine
Antiretroviral Therapy
Highly Active
medicine
Humans
030212 general & internal medicine
Myocardial infarction
lcsh:Science
Multidisciplinary
Cholesterol
business.industry
lcsh:R
Cholesterol
HDL
Lipid metabolism
Infectious Diseases/HIV Infection and AIDS
medicine.disease
Lipid Metabolism
3. Good health
Glucose
chemistry
Cardiovascular Diseases
Immunology
Chronic Disease
HIV-1
Interleukin-2
lcsh:Q
medicine.symptom
business
Cardiovascular Disorders/Myocardial Infarction
medicine.drug
Research Article
Zdroj: PLoS ONE
PLoS ONE, Vol 3, Iss 4, p e2021 (2008)
ISSN: 1932-6203
Popis: Background Concern about costs and antiretroviral therapy (ART)-associated toxicities led to the consideration of CD4 driven strategies for the management of HIV. That approach was evaluated in the SMART trial that reported an unexpected increase of cardiovascular events after treatment interruption (TI). Our goal was to evaluate fasting metabolic changes associated with interruption of antiretroviral therapy and relate them to changes of immune activation markers and cardiovascular risk. Methodology ACTG 5102 enrolled 47 HIV-1-infected subjects on stable ART, with
Databáze: OpenAIRE
Externí odkaz: